Search results
Results from the WOW.Com Content Network
However, I think it's a good choice for income investors, with its forward dividend yield of nearly 4% and an improving outlook. Should you invest $1,000 in Viatris right now? Before you buy stock ...
Until recently, Viatris (NASDAQ:VTRS) was considered a value play among drug stocks. But after its recent earnings report, and announced sale of a key asset? The generic drug maker has been deemed ...
For premium support please call: 800-290-4726 more ways to reach us
In 1976 the stock moved to the National Association of Securities Dealers Automated Quotations . Their final stock move was in 1986, when their stock became available for trade on the New York Stock Exchange under the ticker symbol MYL. Prior to the Viatris combination, the stock was traded on the NASDAQ.
Viatris (VTRS) beats on Q3 earnings and sales. The company raises the lower end of its annual revenue guidance. Skip to main content. 24/7 Help. For premium support please call: 800-290-4726 ...
When it made its debut last November, Viatris (VTRS) was touted as a value-unlocking divestiture. The pharmaceutical company, formed when Pfizer (PFE) merged its Upjohn unit with Mylan NV, started ...
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn , a legacy division of Pfizer , on November 16, 2020.
Viatris expects full-year earnings in the range of $2.56 to $2.71 per share, with revenue in the range of $14.6 billion to $15.1 billion. ... Access a Zacks stock report on VTRS at https://www ...